CAPRICOR THERAPEUTICS, INC.

CAPR - CIK 0001133869

Market cap$1.49 B

Rank#2326

SEC filings943

CAPRICOR THERAPEUTICS, INC. trades as CAPR and has a market capitalization of $1.49 B, making it the #2326 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$105.04M. This page tracks CAPRICOR THERAPEUTICS, INC. through 943 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$0.00FY 2025

Net income (latest FY)-$105.04MFY 2025

Operating cash flow (latest FY)-$69.81MFY 2025

Total assets (latest FY)$355.95MFY 2025

Financial performance

Net profit margin expanded from -470.3% to -181.7% over the same period - every figure below comes from the company's audited annual filings.

CAPR annual revenueView details

Key statistics

Market cap: $1.49 B
Share price (derived)market cap / shares outstanding: $25.69
EPS (diluted)FY 2025: $-2.26
Shares outstandingas of 2026-05-11: 0.06B
Total equityas of 2026-03-31: $278.70M
Return on equity: -37.7%
Cash & equivalentsas of 2026-03-31: $105.42M
Stock buybacksFY 2020: $0.00

Latest filings

Filing	Type	Filed
144/A	-	2026-05-19
Insider sale notice	144	2026-05-19
Insider trade	4	2026-05-19
Insider trade	4	2026-05-14
Quarterly report	10-Q	2026-05-13
Major company event	8-K	2026-05-12
Major company event	8-K	2026-05-07
Insider trade	4	2026-05-04

Browse the full filing history (943 filings)

Recent press releases

Capricor Therapeutics Expands Commercial Leadership Team2026-05-28
Capricor Therapeutics Expands Commercial Leadership Team
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update2026-05-12
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update :: Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy2026-05-07
Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 122026-05-04
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 :: Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting2026-04-22
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting :: Capricor Therapeutics, Inc. (CAPR)

Similar companies

The largest companies sharing CAPRICOR THERAPEUTICS, INC.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T CAPR vs LLY

JNJJohnson & Johnson$573.98 B CAPR vs JNJ

ABBVAbbVie Inc.$399.47 B CAPR vs ABBV

MRKMerck & Co., Inc.$293.16 B CAPR vs MRK

AZNAstraZeneca PLC$286.27 B CAPR vs AZN

Frequently asked questions

What is CAPRICOR THERAPEUTICS, INC.'s market cap?

CAPRICOR THERAPEUTICS, INC. (CAPR) has a market capitalization of $1.49 B as of 2026-06-10, ranking #2326 among US-listed companies.

How much revenue does CAPRICOR THERAPEUTICS, INC. make?

CAPRICOR THERAPEUTICS, INC. reported revenue of $0.00 for fiscal year 2025, a decrease of 100.0% year over year.

Is CAPRICOR THERAPEUTICS, INC. profitable?

In its latest fiscal year CAPRICOR THERAPEUTICS, INC. reported a net loss of $105.04M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.